

Status: Currently Official on 17-Feb-2025
 Official Date: Official as of 01-Dec-2020
 Document Type: USP Monographs
 DocId: GUID-22728900-D589-428C-A4E0-26AC54783530_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M28095_04_01
 DOI Ref: d9xuy

© 2025 USPC
 Do not distribute

Doxazosin Tablets

DEFINITION

Doxazosin Tablets contain an amount of Doxazosin Mesylate equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of doxazosin ($C_{23}H_{25}N_5O_5$).

IDENTIFICATION

• **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

Add the following:

▲ **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-Dec-2020)

ASSAY

Change to read:

• PROCEDURE

Buffer: Transfer 3.4 g of [monobasic potassium phosphate](#) into a 1-L flask, and add 800 mL of [water](#) and 4.0 mL of [triethylamine](#) to dissolve. Adjust with [phosphoric acid](#) to a pH of 4.5, and dilute with [water](#) to volume.

Mobile phase: [Methanol](#) and *Buffer* (55:45)

Diluent: [Methanol](#) and [0.1 N hydrochloric acid](#) (90:10)

Standard solution: 0.049 mg/mL of [USP Doxazosin Mesylate RS](#) in *Diluent*. ▲Sonicate to dissolve as needed.▲ (USP 1-Dec-2020)

Sample stock solution: ▲Nominally ($L/25$) mg/mL of doxazosin prepared as follows, where L is the label claim in mg/Tablet.▲ (USP 1-Dec-2020)
 Transfer 10 Tablets, whole or ground, into a 250-mL volumetric flask, add 10 mL of [water](#), and sonicate until the Tablets are disintegrated. Add 150 mL of *Diluent*, sonicate for 30 min, and dilute with *Diluent* to volume.

Sample solution: Nominally 0.04 mg/mL of doxazosin in *Diluent* from *Sample stock solution*. ▲For Tablets labeled to contain 1 mg, use the corresponding *Sample stock solution* directly. Centrifuge a portion of the solution and use the filtrate.▲ (USP 1-Dec-2020)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 245 nm. ▲For *Identification B*, use a diode array detector in the range of 200–400 nm.▲ (USP 1-Dec-2020)

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Column temperature: 40°

Flow rate: 1 mL/min

Injection volume: 20 μL

▲**Run time:** NLT 1.6 times the retention time of doxazosin▲ (USP 1-Dec-2020)

System suitability

Sample: *Standard solution*

Suitability requirements

▲ (USP 1-Dec-2020)

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of doxazosin ($C_{23}H_{25}N_5O_5$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of doxazosin from the *Sample solution*

r_S = peak response of doxazosin from the *Standard solution*

C_s = concentration of [▲USP Doxazosin Mesylate RS▲](#) (USP 1-Dec-2020) in the *Standard solution* (mg/mL)

C_u = nominal concentration of [▲doxazosin▲](#) (USP 1-Dec-2020) in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of doxazosin, 451.48

M_{r2} = molecular weight of doxazosin mesylate, 547.58

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

• [DISSOLUTION \(711\)](#).

Medium: [0.01 N hydrochloric acid](#); 900 mL

Apparatus 2: 50 rpm

Time: 30 min

Standard solution: A known concentration of [USP Doxazosin Mesylate RS](#) in *Medium*.

Sample solution: Pass a portion of the solution under test through a suitable filter. Dilute with *Medium* as needed.

Instrumental conditions

Mode: UV

Analytical wavelength: 246 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of doxazosin [▲▲](#) (USP 1-Dec-2020) ($C_{23}H_{25}N_5O_5$) [▲▲](#) (USP 1-Dec-2020) dissolved:

$$\text{▲Result} = (A_u/A_s) \times C_s \times V \times (M_{r1}/M_{r2}) \times (1/L) \times 100$$

A_u = absorbance of the *Sample solution*

A_s = absorbance of the *Standard solution*

C_s = concentration of [USP Doxazosin Mesylate RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 900 mL

M_{r1} = molecular weight of doxazosin, 451.48

M_{r2} = molecular weight of doxazosin mesylate, 547.58

L = label claim of doxazosin (mg/Tablet) [▲](#) (USP 1-Dec-2020)

Tolerances: NLT 70% (Q) of the labeled amount of doxazosin [▲▲](#) (USP 1-Dec-2020) ($C_{23}H_{25}N_5O_5$) [▲▲](#) (USP 1-Dec-2020) is dissolved.

• [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

Add the following:

▲• **ORGANIC IMPURITIES:** Protect the solutions containing doxazosin from light.

Buffer: 3.4 g/L of [monobasic potassium phosphate](#), prepared by dissolving 3.4 g of [monobasic potassium phosphate](#) in 1 L of [water](#)

Solution A: Mix 90 mL of [acetonitrile](#) with 920 mL of *Buffer*. Add 1 mL of [triethylamine](#) and adjust with [phosphoric acid](#) to a pH of 3.0.

Solution B: Mix 500 mL of [acetonitrile](#) with 500 mL of *Buffer*. Add 1 mL of [triethylamine](#) and adjust with [phosphoric acid](#) to a pH of 3.0.

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	100	0
7.0	100	0
35.0	0	100
45.0	0	0